Altimmune (ALT)
(Delayed Data from NSDQ)
$7.37 USD
+0.15 (2.08%)
Updated May 13, 2024 04:00 PM ET
After-Market: $7.38 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 37% (94 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.57 | 1.52 | 9.99 |
Current Quarter Estimate | -0.36 | -2.04 | 57.00 |
Year Ago Quarter Estimate | -0.32 | -0.59 | 52.54 |
Next Quarter Estimate | -0.40 | -2.00 | 61.00 |
Next Year Estimate | -2.13 | 6.92 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | -6.29 | 11.80 | 15.67 |
Next Year | -40.13 | 15.40 | 9.31 |
Last 5 Years | NA | 4.90 | 8.10 |
Next 5 Years | NA | 22.20 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | 2.96 | 1.91 |
Price/Cash Flow (MRFY) | NA | 9.59 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -22,645.37% | 0.82% |
Return on Equity (TTM) | -46.96% | -24.69% |
Debt to Equity (MRQ) | 0.00 | 0.04 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.